FOR IMMEDIATE RELEASE
JFC ENCOURAGED BY EARLY CLINICAL TRIAL RESULTS
JFC's partner TyRx Pharmaceuticals announced the initial, interim clinical results from its AIGISRX™ Antibacterial Envelope Retrospective Registry.
AIGIS is an anti-bacterial mesh envelope developed to deliver anti-microbial agents that help provide protection against infections associated with implanted pacemakers and cardioverter defibrillators. AIGIS also securely holds a pacemaker (PM) or implantable cardioverter defibrillator (ICD) in order to create a stable environment when implanted in the body. The AIGISRX™ Antibacterial Envelope is made with cGMP polymer materials manufactured by JFC Technologies.